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Abstract
Background: Quantitative indicators are needed in order to define priorities, plan policies and evaluate
public health interventions in mental health. The aim of this study was to assess the contribution of a
large and exhaustive French national administrative database to study and monitor treated depression by
comparing the prevalence and characteristics of the population using significant healthcare resources for
depression as identified by different estimation methods and sources and to discuss the advantages and
drawbacks of these methods.
Methods: This study included the French population covered by the main health insurance scheme in
2012 (Régime général, 86% of the insured French population). Data were extracted from the French health
insurance claim database (SNIIRAM), which contains information on all reimbursements, including treatments
and hospital stays in France. The following distinct sources of the SNIIRAM were used to select persons with
depression: diagnoses of long-term or costly conditions, data from national hospital claims and data
concerning all national health insurance reimbursements for drugs.
Results: In 2012, we included 58,753,200 individuals covered by the main health insurance scheme; 271,275
individuals had full coverage for depression; 179,470 individuals had been admitted to a psychiatric hospital
and 66,595 individuals admitted to a general hospital with a diagnosis of depression during a 2-year timeframe and
144,670 individuals had more than three reimbursements for antidepressants during the study year (with a history of
hospitalisation for depression during the past 5 years). Only 16% of individuals were selected by more than one source.
Conclusions: We propose an algorithm that includes persons recently hospitalised for depression, or with a
history of hospitalisation for depression and still taking antidepressants, or with full coverage for depression
as a specific long-term or costly condition, yielding a prevalence estimate of 0.93% or 544,105 individuals. Changes in
the case selection methodology have major consequences on the frequency count and characteristics of the selected
population, and consequently on the conclusions that can be drawn from the data, emphasizing the importance of
defining the characteristics of the target population before the study in order to produce relevant results.
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Background
According to the World Health Organisation, 14% of the
global burden of disease is attributed to mental health
disorders [1], among which unipolar depression is the
second leading cause of life years with disability world-
wide. Depression per se is a major contributor to the
global burden of disease [2, 3] and is associated with a
high economic burden [4, 5], making it a major public
health priority.
Quantitative indicators are needed in order to define
priorities, plan policies and evaluate public health inter-
ventions in mental health. Few studies have estimated
the prevalence of depression in the general population
in France, and they were based on medical interviews,
symptom questionnaires, self-reported diagnoses, treat-
ments, or full health insurance coverage with a diagnosis
of depression in administrative databases [6]. Further-
more, as studies conducted according to different meth-
odologies can provide different perspectives on a
particular issue, multiple sources of information may be
complementary to more accurately study depression [7].
Data about hospital healthcare use in psychiatry are
now almost exhaustively available in France with the
recent improved quality of the national hospital claim
databases in psychiatry [8], in addition to other data
sources from general hospitals or insurance claims. The
contribution of a large and exhaustive national adminis-
trative database to study and monitor treated depression
should be assessed, especially in terms of the potential
contribution of combining information from different
sources. Although such studies already exist in North
America [9–13], their findings may not apply to the
French setting with its specific healthcare system and in-
formation sources. Furthermore it may be of interest to
compare United States or Canadian results with data
from another setting.
The French national health insurance scheme,
CNAMTS, has developed a tool to study the medical
and economic burden and the care pathway of multiple
chronic diseases, including psychiatric disorders [14].
Various methods were tested to select people who had
received care for depression, which yielded different
populations. The most appropriate and accurate method
may vary depending on whether the study goal is epi-
demiological monitoring, care pathway description or
medico-economic analysis. As an insurance scheme, the
goal of the CNAMTS study was to estimate the popula-
tion receiving healthcare as well as the amount of
healthcare resources allocated to depression, and was
therefore designed to select a population using signifi-
cant healthcare resources as a result of this disease. This
study was a first step before analysing factors such as
trends over time and cost patterns, regional health pro-
files, care pathways, outcomes, comorbidities, etc.
The objective of this study was (1) to examine the
prevalence and characteristics of the population using
significant healthcare resources for depression as identi-
fied by different estimation methods and sources and (2)




This study was restricted to the population covered by
the main health insurance scheme (Régime général),
which represented 86% of the insured French population
in 2012, as not all information was available for the
other insurance schemes at that time. Almost the entire
French population is insured [15]. All persons with at
least one reimbursement for medical care in 2012 were
included in the study. Same-sex twins were excluded
from the study because of linkage problems specific to
this population.
Data
Data were extracted from the French health insurance
claim database (SNIIRAM), which contains informa-
tion on all reimbursements, including treatments,
diagnostic and therapeutic procedures, and hospital
stays in France for almost the entire population. The
database is not public; analyses by CNAMTS were
allowed by CNIL, the independent French administra-
tive regulatory body whose mission is to ensure that
data privacy law is applied to the collection, storage,
and use of personal data [16]. Diagnoses related to
outpatient visits and results of procedures are not
reported in the database [17].
Selection of persons with depression
The following distinct sources of the SNIIRAM were
used to select persons with depression:
Source 1: Diagnoses of long-term or costly conditions
(Affections de Longue Durée, ALD). Patients with
specific long-term or costly conditions may require
full coverage for all their condition-related health
expenditures upon request by their family doctor
and after approval by a health insurance fund
medical officer (médecin-conseil) [18].
Source 2: Data from national hospital claims
(Programme de Médicalisation des Systèmes
d’Information, PMSI) for all inpatient and day-case
admissions in public and private general and
psychiatric hospitals, containing medical diagnoses
defined as ICD-10 codes. In both general and
psychiatric hospitals, a principal diagnosis is
defined as the main reason for admission, while
associated diagnoses provide information about
Filipovic-Pierucci et al. BMC Psychiatry  (2017) 17:1 Page 2 of 10
conditions that significantly influenced care during
the hospital stay [19].
Source 3: Data concerning all national health insurance
reimbursements for drugs, laboratory tests and
outpatient medical procedures. Individuals receiving
reimbursements for antidepressants (N06A section
of the ATC classification except for oxitriptan)
can be identified. However, these databases do
not contain direct information about the diagnosis
justifying the prescription, and these drugs are
not specific for depression, as they can also be
prescribed for other conditions (bipolar disorders,
anxiety or chronic pain). An antidepressant
prescription is typically valid 1 month.
All three sources were not considered to be equally
reliable for identifying patients with depression. Reliabil-
ity of the sources was assessed as follows: for the pur-
pose of identifying individuals suffering from depression,
full coverage for depression as a specific long-term or
costly condition (source 1) was more reliable than the
hospital claims database (source 2), which was more reli-
able than reimbursement for antidepressants (source 3).
In the hospital claims database, associated diagnoses
reported during general hospital stays were assumed to be
less reliable than those reported during psychiatric hos-
pital stays. The reasons underlying this classification of
source reliability included (1) the mode of acquisition of
the information (diagnoses resulting from medical inter-
views were regarded as more reliable than hospital diag-
nostic codes sometimes coded by non-medical staff,
themselves regarded as a more reliable diagnostic markers
than prescription drugs) and (2) what was as stake when
the information was coded (hospital diagnostic codes that
had no consequence on costs were regarded as less reli-
able than codes influencing costs or giving access to bene-
fits). These reasons are described and discussed more
thoroughly in the Merits and drawbacks of the various
methods section of the Discussion section of this article.
Accordingly, five estimation methods with decreasing
order of reliability were defined. ICD-10 codes F32 to F39
were used in all estimation methods to identify depression
(either as a full health coverage code or as a principal or
associated diagnosis). At least three reimbursements for
antidepressants were used to identify treatment by anti-
depressant. Hospital stays in the last 5 years with a princi-
pal or associated diagnosis of depression were used to
identify principal diagnosis history and associated diagno-
sis history of depression respectively.
– Method A (Full coverage for depression): Selection
of individuals with full coverage for depression as a
specific long-term or costly condition during the
study (source 1);
– Method B (Hospitalisation for depression): Selection
of individuals with depression as principal or
associated diagnosis in a psychiatric hospital stay
or as principal diagnosis in a general hospital stay
using two timeframes: (a) the current calendar
year and (b) the last two calendar years (source 2).
Calendar years were used for technical reasons.
– Method C (Current antidepressant treatment +
History of hospitalisation during the past 5 years):
Selection of individuals treated by antidepressant
and with a general hospital principal diagnosis
history of depression or a psychiatric hospital
principal or associated diagnosis history of
depression (combination of sources 2 and 3);
– Method D (Hospitalisation in a general hospital with
an associated diagnosis of depression): Selection of
individuals with depression as associated diagnosis
in a general hospital stay using two timeframes:
(a) the current calendar year and (b) the last two
calendar years (source 2);
– Method E (Current antidepressant treatment +
History of hospitalisation in a general hospital
with an associated diagnosis of depression during
the past 5 years): Selection of individuals treated
by antidepressant and with a general hospital
associated diagnosis history of depression
(combination of sources 2 and 3).
Individuals with a hospital diagnosis of bipolar dis-
order (ICD-10 codes F30 or F31) in the last 5 years
or a specific treatment for bipolar disorder (lithium,
divalproex or valpromide) were not included in the
study.
Statistical analysis
Populations selected by these different methods were de-
scribed by age and gender. The incremental contribution
of each method (e.g. the contribution of adding method
B in the presence of method A) was assessed. Frequency
counts were rounded to the nearest 5.
Mortality rates for a given method were calculated
as the number of individuals selected by the method
who died during the year divided by the total num-
ber of individuals selected by the method. Mortality
was measured by the administrative vital status of
the individuals, as informed by French civil registry
data.
Qualitative variables were described by frequency
counts, and quantitative variables were described by
means. All reported differences were statistically signifi-
cant with an alpha risk of 5%. Because of the high statis-
tical power of this study, statistically significant
differences were only reported and discussed when they
were considered to be clinically relevant. Statistical
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analysis was performed with SAS software version 9.2
and proportional Venn diagrams were drawn using
EulerAPE software [20].
Results
Frequency counts by data sources
In 2012, 58,753,200 individuals covered by the main
health insurance scheme received at least one reim-
bursement for any cause [21]. Frequency counts by esti-
mation method are presented in Table 1. In this
population, method A identified 271,275 individuals with
full coverage for depression; method B identified a total
of 229,020 individuals: 109,260 individuals who had been
admitted to a psychiatric hospital with a principal or as-
sociated diagnosis of depression and 34,630 individuals
admitted to a general hospital with a principal diagnosis
of depression during the study year. Those counts in-
creased to 179,470 and 66,595, respectively, with aggre-
gate counts over a 2-year timeframe, for a total
aggregate count of 229,100 individuals. Method C identi-
fied 137,110 individuals with more than three reimburse-
ments for antidepressants during the study year and
with a history of hospitalisation for depression during
the past 5 years in a psychiatric hospital, 51,420 in a
general hospital, for a total of 144,670 individuals with
aggregate counts over psychiatric and general hospitals.
Frequency counts and intersections between data
sources are presented using a Venn diagram (Fig. 1);
only 16% of individuals were selected by more than one
method. Individuals taking antidepressants and with a
history of hospitalisation for depression (method C)
were more frequently selected by another source (44% of
these individuals) than individuals with hospitalisation in
the past 2 years (method B) and individuals with full
coverage for depression (method B), 30 and 20%,
respectively, were also selected by another source.
Method D identified 213,010 individuals who were
admitted to a general hospital with an associated diagno-
sis of depression during the current year (340,270 with
aggregate counts over a 2-year timeframe, only 14% were
detected by another source). Method E identified
266,890 individuals who were treated with antidepres-
sants and who had a history of hospitalisation with an
associated diagnosis of depression during the last 5 years
(by construction, most of these individuals were already
detected by method D).
Incremental contribution of data sources
The incremental contribution of data sources was stud-
ied in order to quantify the specific contribution of a
data source in the presence of the other sources. In
addition to the 271,275 individuals with full coverage for
depression (method A), method B (selecting individuals
with a hospital diagnosis except for general hospital
associated diagnoses for depression) added 192,255 indi-
viduals to the total (113,435 hospitalised during the
current year and another 78,820 hospitalised during the
previous year, aggregate counts over psychiatric and gen-
eral hospitals). Selecting persons taking treatments for
depression and with a history of hospitalisation for
depression (method C) added another 80,570 individuals
(aggregate counts over psychiatric and general hospitals),
for a total of 544,105 individuals.
Furthermore, method D (selecting individuals with an
associated diagnosis of depression during a general hos-
pital stay) added another 291,925 persons to this total
(164,660 individuals hospitalised during the current year
and another 127,265 individuals hospitalised during the
previous year). Finally, method E added 133,270 individ-
uals (persons with a treatment for depression and a
history of hospitalisation for depression defined as a
general hospital associated diagnosis of depression in the
last 5 years), for a total of 969,300 individuals.
This incremental method yielded prevalence estimates
ranging from 0.46% for the most conservative method
(method A–only the population with full health insur-
ance coverage for depression) to 1.65% for the less
conservative method (using all methods A to E).
Intermediate methods that combined full health insur-
ance coverage for depression with hospitalisations for
depression, but not including general hospital stays
with associated diagnoses of depression yielded esti-
mates ranging from 0.61% (methods A + B) to 0.93%
(methods A + B + C).
Population characteristics by data sources
Population characteristics varied according to the data
source (Table 1). Individuals with full coverage for de-
pression as a specific long-term or costly condition,
those taking antidepressants with a history of hospital-
isation for depression and those hospitalised with an
associated diagnosis of depression were older than the
individuals selected by the other sources (58–62% vs.
50–54%). The proportion of persons taking antidepres-
sants was higher in the population admitted to specia-
lised psychiatric hospitals and the population with full
coverage for depression compared to the population
hospitalised in general hospitals (72–75% respectively vs.
55%). The mortality rate during the study period was
twice as high for persons selected only on the basis of
associated diagnoses reported by general hospitals than
for other populations (7–9% vs. 2–4%).
The population identified by methods A + B + C was
described (Table 2). A majority of the population had
reimbursements for antidepressants or anxiolytics
(74.3 and 61.3% respectively), and around 30% has re-
imbursements for neuroleptics or hypnotics. The total
national health insurance spending for this population
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was 6283 million euros, with more than half this cost
in hospital fees (3697 million euros). The proportion
of individuals eligible for specific coverage for the less
well-off (Couverture Médicale Universelle Complémen-
taire, used as a marker of socioeconomic status) was
14.4%, more than double the national average (6.6%).
The calculation of CMUC rates was restricted to the
population below 60 because individuals are eligible
to different benefits after 60.
Discussion
Main results
Estimates of the prevalence of people using significant
healthcare resources for depression in France vary ac-
cording to the method used when analysing adminis-
trative databases, ranging from 0.46 to 1.65% from
the most conservative to the broadest method, re-
spectively, and from 0.61 to 0.93% when using inter-
mediate methods. We propose an algorithm to study
the population with significant healthcare use during
the past 2 years that includes persons recently hospi-
talised for depression, or with a history of hospitalisa-
tion for depression and still taking antidepressants, or
with full coverage for depression as a specific long-
term or costly condition (method A, B and C). This
algorithm yields a prevalence estimate of 0.93% or
544,105 individuals in the major health insurance
scheme.
Population surveys provide much higher prevalence
estimates of major depressive disorder during a 12-
month period, ranging from 5 to 8%: 5.0% [22], or 6.0%
[23] and 7.8% [24], depending on the survey. These esti-
mates are much higher than our highest estimate of
1.65% over a 2-year period. These discrepancies are
similar to those reported in a review and assessment of
the performance of administrative data for depression
surveillance in North America [9] that found that, while
these data provide estimates with high specificity and
positive predictive value, their sensitivity may remain
low. This gap can be explained by differences in defin-
ition and methodology: whereas surveys are designed to
identify individuals within the entire population present-
ing clinical criteria of major depressive disorder, the
present study selected individuals using significant
healthcare resources, representing only a fraction of the
population with major depressive disorder. As psycho-
therapy is not currently reimbursed in France, patients
with major depressive disorder may well receive appro-
priate ambulatory care with or without antidepressant
treatment and without requiring hospitalisation or full
health insurance coverage for depression. These patients
are not included in our estimates.
Fig. 1 Numbers and proportions of individuals who received care for depression, derived from various data sources, in the SNIIRAM 2012.
Method A: full coverage for depression as a specific long-term or costly condition. Method B: hospitalisation for depression in a general hospital
(principal diagnosis of depression) or psychiatric hospital (principal or associated diagnosis of depression) during the last 2 years. Method C: taking
antidepressants and a personal history of hospitalisation for depression in the last 5 years. Individuals selected exclusively on the basis of associated
diagnoses in general hospital stays or personal history of hospitalisation for depression (3–5 years previously) were not included in this
diagram. Numbers are rounded to the nearest 5
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Merits and drawbacks of the various methods
Methods based exclusively on attribution of full health
insurance coverage for depression may fail to identify a
large proportion of the target population, by mostly
selecting individuals for whom the disease represents a
significant clinical and financial burden. Even in this
situation, full coverage is less likely to be requested when
it has already been attributed for another chronic disease
(such as a cardiovascular disease, diabetes or cancer) or
if the person is eligible for specific coverage for the less
well-off (Couverture Médicale Universelle Complémen-
taire) or has complementary private insurance to cover
the additional economic burden. Full health insurance
coverage for depression is therefore likely to be an insuf-
ficiently sensitive marker; this property has already been
demonstrated for other diseases such as cancer [25].
This finding was confirmed by our analysis, in which
most people hospitalised for depression did not have full
health insurance coverage. However, as full coverage for
severe chronic depression is attributed by a health insur-
ance physician at the request of the patient’s doctor, and
as it must be renewed on request every 5 years, this data
source is probably highly specific [18].
Principal diagnoses from hospital stays are probably
reliable markers of severe depression because they con-
stituted the reason for admission of these individuals
[19]. Even in non-psychiatric hospitals, they correspond
to forms of depressions that are deemed to be suffi-
ciently severe to justify admission. Furthermore, princi-
pal diagnoses play an important role in calculation of
the cost of the hospital stay and are consequently subject
to strict scrutiny by both hospital medical record sum-
marisers and national health insurance. When used as
markers of a history of severe depression, principal diag-
noses allow the selection of a population with suffi-
ciently severe depression to justify a hospital stay in the
previous 5 years and who still need treatment with
antidepressants.
The value of associated diagnoses during a psychiatric
hospital stay may be similar to that of the principal diag-
nosis, as this diagnosis was reported by a psychiatrist.
On the other hand, associated diagnoses from general
hospital stays are likely to be less reliable. Although
associated diagnoses should theoretically only provide
information about illnesses that played a significant role
during the hospital stay, they are also widely used to
report history or concomitant diseases that, on their
own, would not have justified hospitalisation [26]. Even
individuals taking antidepressants and presenting an
associated diagnosis of depression could actually be pri-
marily treated for a severe organic disease. This possibil-
ity was confirmed by our data showing that this
population had a higher mortality rate than the other
groups. The inclusion of this population markedly in-
creased prevalence estimates compared to the relative
contribution of other more reliable data sources. While
this population may suffer from milder forms of depres-
sion, individuals with associated diagnoses reported dur-
ing general hospital stays should probably therefore not
be included in this study, which was designed to select
the population using significant healthcare resources for
severe depression.
Extending the selected hospital stay timeframe from 1
to 2 years increased prevalence estimates by 0.14%.
However, it is likely that depression which was suffi-
ciently severe to require hospitalisation was not com-
pletely resolved 1 year later, therefore justifying the
inclusion of hospital stays during the previous 2 years.
Since this study was based on calendar years, actual
Table 2 Characteristics of the population identified by the












Neurological or degenerative diseases 9.0
Inflammatory diseases or HIV 4.0
End-stage kidney disease 0.2






Any of the above 83.9
Amount reimbursed (millions of euros)






a Full health coverage for individuals with an annual income below the
poverty threshold. Analysis restricted to the population younger than 60
b At least three reimbursements
c Excluding pharmaceuticals
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intervals between hospital discharge and study inclusion
may vary from 1 to 24 rolling months. The proportion of
individuals treated by antidepressants in our study was
similar for persons hospitalised during the current year
and persons hospitalised during the previous year, con-
firming that this population still suffered from depression
or still required treatment to consolidate recovery.
Most individuals were selected by only one method,
which highlights the value of combining several data
sources, especially in the presence of sources with
low sensitivity such as full health insurance coverage
for depression. To our knowledge, this is the first
study in France using these combined sources to
study depression [6].
All ICD-10 codes for depression were used, including
codes usually reserved for milder forms of depression
(F32.0 and F32.9) to allow for inaccurate diagnosis cod-
ing based on the following rationale: severity of depres-
sion is determined by whether hospitalisation was
deemed necessary more than by the ICD-10 code itself,
especially since the objective of this study was to select
persons with depression based on healthcare use criteria
(such as hospital stays) and not purely on clinical
criteria. The same codes have been used to define
depression in an electronic health records-based study
in the United Kingdom [27]. Individuals with bipolar
disorder codes were not included in this study, but per-
sons with bipolar disorder in a depressive phase in
whom their specific condition had never been previously
diagnosed may have been incorrectly included in all
sources (full coverage, treatments or hospitalisations).
Antidepressant drugs are not specific of depression, as
they may also be prescribed for chronic pain or anxiety
[28, 29]. Furthermore, using drugs as a marker may se-
lect individuals with milder forms of depression not
resulting in significant healthcare use. For both of these
reasons, antidepressant treatment was only considered
when it was combined with a history of hospitalisation
for depression during the past 5 years, which is both
specific of the disease and a better marker of significant
healthcare use [29]. As an order of magnitude, 4.4 mil-
lion people (8.7% of the population) in France were
treated with an antidepressant in 2011 [30].
Limitations and future directions
As the databases used in this study only contain infor-
mation on individuals with at least one reimbursement
for medical care, this study was unable to detect the
population with no contact with the healthcare system
during the study period because of personal choices or
problems of accessibility to health services. This draw-
back could constitute a major problem from an epi-
demiological or a need for care perspective. The
proportion of the population without reimbursement in
2013 can be estimated to be around 5%, but varies ac-
cording to gender, age and health status. It would there-
fore be difficult to estimate the impact of this population
on the results of this study. On the other hand, insur-
ance claim data are appropriate from the perspective of
this study, as the primary objective was to select a popu-
lation using significant healthcare resources related to a
particular medical problem, and to assess the amount of
resources allocated to this problem. Monitoring of the
population with a significant healthcare use is particu-
larly important from a public health, healthcare manage-
ment and policy planning perspective. Finally, the
population covered by the major health insurance
scheme (86% of the French population) may not be com-
pletely representative of the entire French population. In
particular, farmers and self-employed workers are not in-
cluded in this insurance scheme.
The development of this algorithm is part of a larger
work by CNAMTS to identify populations with various
diseases in the SNIIRAM. Results from this research are
analysed to produce a yearly report on spending per
pathology and spending trends over time [21], or to
study the national burden of more specific diseases [31].
This data was also used to compare regional profiles of
various pathologies in France overseas departments [32],
and could be employed more widely at a regional level
to better inform local health policies. More specific lon-
gitudinal cohort studies are also being developed from
this data to analyse pathway of care, outcomes, or
comorbidities [33].
Conclusion
Combined analysis of administrative databases is an al-
ternative and complementary approach to medical
interview-based epidemiological surveys [9, 10], which
constitute the gold standard. Medical interview-based
surveys can provide estimates that include individuals
who had no contact with the healthcare system, who did
not seek care for their disease, or for whom the contact
cannot be identified as a marker in an administrative
database. However, these studies are expensive, must be
performed on small random samples and take a long
time to be implemented and to provide results. Working
on medical records and administrative databases has a
low added cost and can rapidly yield results on the re-
cent situation and on secular trends, as the data have
already been collected for other reasons. In the present
study, we propose an algorithm to study the population
with significant healthcare use during the past 2 years
that will include persons recently hospitalised for de-
pression, or with a history of hospitalisation for depres-
sion and still taking antidepressants, or with full health
insurance coverage for depression as a specific long-
term or costly condition.
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These data provide relevant information to stake-
holders for public health, healthcare management or
policy planning [34] that must be analysed by taking
their limitations into account.
This study shows that changes in the case selection
methodology have major consequences on the frequency
count and characteristics of the selected population, and
consequently on the conclusions that can be drawn from
the data. This finding is important for mental health re-
searchers contemplating similar approaches: it empha-
sizes the importance (1) to define precisely the target
population before the study and (2) to carefully consider
how and why the administrative data is produced in the
first place in order to produce relevant results.
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